Apyx Medical Corporation (NASDAQ: APYX) announced on September 29, 2026, the publication of new clinical data in Plastic and Reconstructive Surgery — Global Open. The study evaluates the effects of the company's Renuvion helium plasma radiofrequency technology on biological markers of skin quality.
The prospective, single-arm, post-market study was conducted at two U.S. investigational sites and involved seven patients undergoing lower rhytidectomy, or facelift, surgery. Six participants completed the Day 180 visit. The study compared Renuvion-treated subdermal tissue against untreated internal control areas.
Key findings from the study at Day 180 include:
- Increased Elastin: Treated tissue demonstrated a 30% increase in elastin fiber density and a 55% increase in elastin staining intensity.
- Reduced Inflammation: Treated tissue showed a 34% reduction in inflammation compared to untreated control tissue.
- Regenerative Remodeling: Human tissue analysis indicated a 27% increase in the incidence of elastin expression.
- Safety: No significant fibrosis, abnormal vascularization, or epithelial disruption was observed.
Physician and patient assessments showed that 100% of participants demonstrated improvement in aesthetic scores. Additionally, 100% of participants reported satisfaction with their treatment outcomes and indicated they would recommend the procedure to others. Participants reported noticeable improvements in skin elasticity, radiance, and youthfulness.
Charlie Goodwin, President and Chief Executive Officer of Apyx Medical, stated that the findings provide direct human histological evidence supporting the clinical benefits of Renuvion observed by surgeons for years.
